Hydroxyrubicin

Hydroxyrubicin is an antitumor agent. Hydroxyrubicin can induce topoisomerase II-mediated DNA cleavage in human c-myc-origin DNA. Hydroxyrubicin induces DNA unwinding. Hydroxyrubicin has a significant inhibitory effect on tumor cells. Hydroxyrubicin can be used for the study of Multidrug-resistant (MDR) leukemia[1][2].

Product Specifications

CAS Number

[73113-90-3]

UNSPSC

12352005

Target

C-Myc

Related Pathways

Apoptosis

Field of Research

Cancer

Smiles

OC1=C2C([C@H](C[C@@](C(CO)=O)(O)C2)O[C@@]3([H])C[C@@H]([C@H](O)[C@H](C)O3)O)=C(O)C4=C1C(C5=CC=CC(OC)=C5C4=O)=O

Molecular Formula

C27H28O12

Molecular Weight

544.50

References & Citations

[1]Solary E, et al. Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance[J]. International journal of cancer, 1994, 58 (1) : 85-94.|[2]Priebe W, et al. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anticancer Drugs. 1993 Feb;4 (1) :37-48.